For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Tramadol Hydrochloride (HCl)-Paracetamol | Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325 mg) for up to a total duration of 6 hours. | None | None | 0 | 1059 | 86 | 1059 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Nausea | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Vomiting | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Headache | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Dizziness | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Lethargy | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Weakness | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Skin itch | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |
| Others | NON_SYSTEMATIC_ASSESSMENT | General disorders | No coding applied | View |